Comparisons
Curated comparisons for the most-searched peptide pairs. Specs, clinical numbers, selectivity, side-effect profile - without marketing fluff.
Comparison
Semaglutide (Ozempic, Wegovy) and Tirzepatide (Mounjaro, Zepbound) are the two FDA-approved GLP-1 peptides that have dominated metabolic research since 2021. The key difference is mechanism — Semaglutide activates only GLP-1, while Tirzepatide is a dual GIP/GLP-1 agonist.
Comparison
Semaglutide is the established GLP-1 mono agonist; Retatrutide is the third generation — a triple GLP-1 + GIP + glucagon agonist from Eli Lilly. Phase 2 shows the strongest numbers in the category.
Comparison
Both peptides are from Eli Lilly — Tirzepatide is the dual GLP-1/GIP agonist (approved), Retatrutide is the triple GLP-1/GIP/glucagon agonist (Phase 3). The comparison is between the established standard and its successor.
Comparison
The two leading regenerative peptides in the category — BPC-157 is a protective fragment from gastric juice (15 AA), TB-500 is the active fragment of Thymosin Beta-4 (G-actin binding). The literature often combines them.
Comparison
Both peptides work on the GH axis but via different mechanisms. Ipamorelin is a GHRP — it triggers the pulse itself. CJC-1295 is a GHRH analog — it amplifies pulse amplitude. Standard protocols combine them.
Comparison
Both relate to the GH axis but act through different mechanisms. AOD-9604 is the modified 176-191 fragment from the C-terminus of growth hormone — purely lipolytic. Tesamorelin is a stabilized GHRH analog — it stimulates the pituitary to release endogenous GH.
Comparison
Both are melanocortin agonists, but with different selectivity and entirely different goals. MT-1 is MC1R-selective — pigmentation (FDA-approved Scenesse for EPP). PT-141 is MC4R-selective — central sexual stimulation (FDA-approved Vyleesi for HSDD in women).
Comparison
Both raise the cellular NAD+ pool but via different mechanisms. NAD+ is administered directly (s.c./IV) — supplementation. 5-Amino-1MQ is the first selective NNMT inhibitor — blocking nicotinamide breakdown to indirectly raise NAD+.
Comparison
The two leading cosmetic peptides, but with entirely different mechanisms. GHK-Cu is a copper tripeptide — stimulates collagen synthesis in the dermis. Argireline is a SNAP-25 mimetic — Botox-like effect via blocking acetylcholine release.
Comparison
Both are metabolic but target different receptors. Liraglutide is first-generation GLP-1 (Saxenda/Victoza, FDA 2010). Cagrilintide is a long-acting amylin analog — a new mechanism category, developed as a Semaglutide partner (CagriSema).
Comparison
The two leading regenerative peptides, but for different tissues. BPC-157 acts at the vascular and motile tissue level (tendons, GI tract, nerves). GHK-Cu acts at the matrix level — skin, fasciae, hair, wound healing.
Comparison
Both are GHRH analogs — but Sermorelin is the minimal 1-29 fragment (Salk Institute, Roger Guillemin), while Tesamorelin is stabilized with trans-3-hexenoyl for DPP-IV resistance. Tesamorelin is FDA-approved; Sermorelin was but is withdrawn.
